Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 11/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887808 | 0.84 | MAOB (0.53) | SSTR3HTTALDH1A1ALOX12SMN1; SMN2 | |
| SCHEMBL3901429 | 0.80 | SSTR3 (0.46) | SSTR3HTTALDH1A1RAB9AALOX12 | |
| SCHEMBL3888172 | 0.79 | HTT (0.60) | HTTALDH1A1RAB9AALOX12NPC1 | |
| SCHEMBL3899240 | 0.78 | MYC (0.61) | SSTR3HTTALDH1A1ALOX12SMN1; SMN2 | |
| SCHEMBL13650298 | 0.76 | MAPT (0.43) | SSTR3HTTALDH1A1ALOX12SMN1; SMN2 | |
| SCHEMBL3888962 | 0.76 | MAOB (0.60) | SSTR3HTTALDH1A1RAB9AALOX12 | |
| SCHEMBL2936924 | 0.76 | KDM1A (0.58) | SSTR3RAB9AKMT2A | |
| SCHEMBL491107 | 0.76 | KDM1A (0.58) | SSTR3RAB9AKMT2A | |
| SCHEMBL2198525 | 0.76 | KDM1A (0.58) | SSTR3RAB9AKMT2A | |
| SCHEMBL2197651 | 0.76 | KDM1A (0.58) | SSTR3RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | claimed |
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | TREH, ADH1A, ADH1C | SSTR3 1363/4885HTT 2789/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.